Patient Registry of Posner-Schlossman Syndrome

• Sponsor: Peking University (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT03233477
• Collaborator: (none)
• Enrollment: 180
• Location: 1
• Anticipated Duration (Months): 120
• Patients Per Site Per Month: 1.5

Study Details

Study Description

Brief Summary

Posner-Schlossman syndrome, or glaucomatocyclitic crisis, is a condition characterized by recurrent, acute attacks of mild, nongranulomatous, anterior uveitis accompanied by markedly elevated intraocular pressure. Most of patients are the 20 to 50-year-old young adults, with unilateral eye involvement. PSS was originally deemed benign, but is now recognized as a relatively rare cause of chronic secondary glaucoma,especially in patients with recurrent episodes. This relatively rare disease is likely the result of the infections of a variety of organisms, and the bulk of literature supports the cytomegalovirus (CMV) as the leading cause.

This study is an observational study that does not interfere with the normal clinical diagnosis and treatment process. The investigators in this study focus on observing the clinical symptoms and outcome of PSS, analyzing the factors that affect the prognosis of PSS, studying the association of its pathogenesis with the psychological status and the behavioral types of PSS patients; exploring the relationship between infection (CMV, HSV, Hp) and PSS; and studying the changes of local and systemic cytokine expression and its significance in patients with PSS.

Condition or Disease	Intervention/Treatment	Phase
Posner Schlossman Syndrome

Study Design

• Study Type: Observational [Patient Registry]
• Anticipated Enrollment: 180 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Patient Registry of Posner-Schlossman Syndrome
• Actual Study Start Date: Jul 31, 2014
• Anticipated Primary Completion Date: Jul 31, 2024
• Anticipated Study Completion Date: Jul 31, 2024

Arms and Interventions

Arm	Intervention/Treatment
Posner-Schlossman Syndrome Inclusion criteria： Clinical diagnosis of Posner-Schlossman Syndrome Able to communicate with doctor and understand this study Exclusion criteria: Not be able to communicate with doctor and understand this study One or more authorized investigators think he or she will suffer from any severe risks from the study
cataract Inclusion criteria： Clinical diagnosis of age-related cataract Prepare for cataract operation Open angle and intraocular pressure is normally at anytime No family history of glaucoma Exclusion criteria: Patients above 65 years old With Secondary ocular hypertension Have the history of receiving any ophthalmologic operation or anti-viral therapy With diabetes mellitus With autoimmune disease Be receiving any therapy that can influence the virus-infection state and biochemical characteristics of serum and aqueous humor, or have received such therapy before one month
primary open-angle glaucoma Inclusion criteria： Both eyes involved Open angle Progressive glaucomatous optic neuropathy Specific visual field loss of glaucoma Intraocular pressure above the up limit of normal people Exclusion criteria: Patients above 65 years old With Secondary ocular hypertension Have the history of receiving any ophthalmologic operation or anti-viral therapy With diabetes mellitus With autoimmune disease Be receiving any therapy that can influence the virus-infection state and biochemical characteristics of serum and aqueous humor, or have received such therapy before one month

Outcome Measures

Primary Outcome Measures

1. demographic characteristics [up to 10 years]

   age, sex, education level, systemic disease， mental state

2. visual acuity [up to 10 years]

   uncorrected visual acuity and best corrected visual acuity

3. intraocular pressure [up to 10 years]

   Goldmann

4. slit-lamp examination [up to 10 years]

   anterior segment

5. fundus photograph [up to 10 years]

   analysis the morphology of optic nerve head

6. OCT [up to 10 years]

   zess

7. visual field [up to 10 years]

   Humphrey visual field

8. blood serum [up to 10 years]

   8ml

9. aqueous humor [up to 10 years]

   0.2ml

10. tissue [in the operation]

    iris and& or trabecular meshwork tissue abandoned in the anti-glaucoma operation

Eligibility Criteria

Criteria

• Ages Eligible for Study: 12 Years to 80 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Volunteer to take part in this study and sign informed consent by oneself or the patient's legal representative

• Clinical diagnosis of Posner-Schlossman Syndrome, age-related cataract, or primary open-angle glaucoma

• Live in Beijing, China or being able to visit the Peking University Third Hospital every year after the beginning of the study or whenever the disease relapses

Exclusion Criteria:

• Fit any exclusion criteria of the patient's group

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Peking University Third Hosipital	Beijing	Beijing	China	100191

Sponsors and Collaborators

• Peking University

Investigators

• Study Director: Chun Zhang, PHD，MD, Peking University Third Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Chun Zhang, Professor, Peking University
• ClinicalTrials.gov Identifier: NCT03233477
• Other Study ID Numbers: IRB00006761-2014166
• First Posted: Jul 28, 2017
• Last Update Posted: Oct 14, 2020
• Last Verified: Oct 1, 2020

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Chun Zhang, Professor, Peking University: Posner Schlossman Syndrome; cytokine expression; cytomegalovirus
• Additional relevant MeSH terms: Syndrome

Study Results

No Results Posted as of Oct 14, 2020